로딩 중…
StockDiggingStockDigging

Eli Lilly and Company

LLY· NYSE
$1411.35-0.44%
2026-11-02

Financials

Valuation Metrics

Eli Lilly and Company's Market Cap is $1.33T. At end of 2025 it was $963.46B. Ranked #11 of 3,116 in US market (top 0.4%), #2 of 1,644 on NYSE (top 0.1%), #1 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$1.33T
Revenue$86.46B
Net Income$27.58B
Total Assets$148.07B
Net Assets$40.27B
Employees50,000
Value
P/E48.17x
P/B32.99x
PEG0.97x
P/S15.37x
EV/EBITDA30.69x
FCF Yield1.48%
Profitability
ROE68.49%
ROA18.63%
Op. Margin46.07%
Revenue Growth45.51%
Earnings Growth49.79%
Financial Health
Debt Ratio267.69%
Total Debt$49.50B
FCF$19.66B
Cash$4.88B
Current Ratio1.39x
Net Debt/EBITDA1.00x
Dividend
Div. Yield0.45%
Div. Growth15.36%
Performance
1Y Return64.08%
1M Return23.49%
From 52W High-2.64%
1Y MDD-23.18%
Trading
Volume2,756,115 shares
Trading Value$3.88B
Per Share
EPS$29.30
BPS$42.78

Company Info

CEO Mr. David A. Ricks
Employees 50,000
HQ Indianapolis, United States

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.